Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma

[1]  A. Rosenwald,et al.  Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. , 2018, Blood.

[2]  J. W. Hansen,et al.  TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. , 2017, Blood.

[3]  R. Houot,et al.  Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma , 2017, The New England journal of medicine.

[4]  D. Rossi,et al.  NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components , 2017, Leukemia.

[5]  R. Advani,et al.  Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499 , 2017, Leukemia.

[6]  M. Czuczman,et al.  18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine–Rituximab , 2017, The Journal of Nuclear Medicine.

[7]  A. Rosenwald,et al.  Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Hortobágyi,et al.  Immunohistochemical correlates of TP53 somatic mutations in cancer , 2016, Oncotarget.

[9]  W. Klapper,et al.  Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.

[10]  K. Seitz.  Mantelzell-Lymphom , 2016, Z Ultraschall in der Medizin.

[11]  S. Ferrero,et al.  The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? , 2016, Haematologica.

[12]  Su-Jin Shin,et al.  MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma , 2016, Histopathology.

[13]  J. Byrd,et al.  Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403 , 2015 .

[14]  W. Klapper,et al.  High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. , 2015, Blood.

[15]  J. Delabie,et al.  miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. , 2015, Blood.

[16]  Y. Natkunam,et al.  Expression Profiles of MYC Protein and MYC Gene Rearrangement in Lymphomas , 2015, The American journal of surgical pathology.

[17]  Su-Jin Shin,et al.  Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour‐associated macrophages , 2014, Hematological oncology.

[18]  E. Kimby,et al.  Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. , 2014, Blood.

[19]  W. Klapper,et al.  Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Linden,et al.  Hematopoietic cell transplantation for mantle cell lymphoma: predictive value of pretransplant positron emission tomography/computed tomography and bone marrow evaluations for outcomes. , 2014, Clinical lymphoma, myeloma & leukemia.

[21]  J. Delabie,et al.  SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study , 2014, British journal of haematology.

[22]  A. Nagler,et al.  Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-d-glucose–positron emission tomography/computed tomography in mantle cell lymphoma? , 2014, Leukemia & lymphoma.

[23]  F. Jardin,et al.  Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index , 2014, Genes, chromosomes & cancer.

[24]  M. Oberley,et al.  Immunohistochemical evaluation of MYC expression in mantle cell lymphoma , 2013, Histopathology.

[25]  Jeffrey A Jones,et al.  Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma , 2013, Bone Marrow Transplantation.

[26]  L. Waldron,et al.  MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Szer,et al.  Prognostic impact of monocyte count at presentation in mantle cell lymphoma , 2013, British journal of haematology.

[28]  F. Cavalli,et al.  Prognostic impact of monocyte count at presentation in mantle cell lymphoma , 2013, British journal of haematology.

[29]  R. Serra,et al.  Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. , 2013, Blood.

[30]  A. Rosenwald,et al.  microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics , 2013, Clinical Cancer Research.

[31]  E. Campo,et al.  SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. , 2013, Blood.

[32]  A. Rosenwald,et al.  CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. , 2013, Blood.

[33]  K. Grønbæk,et al.  MicroRNAs in mantle cell lymphoma , 2013, Leukemia & lymphoma.

[34]  F. Cavalli,et al.  Risk factors of central nervous system relapse in mantle cell lymphoma , 2013, Leukemia & lymphoma.

[35]  C. Kim,et al.  Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. , 2012, American journal of clinical pathology.

[36]  E. Giné,et al.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. , 2012, Cancer research.

[37]  E. Kimby,et al.  Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur , 2012, British journal of haematology.

[38]  A. Goy,et al.  Post‐treatment (not interim) positron emission tomography‐computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R‐HyperCVAD , 2012, Cancer.

[39]  B. Sander,et al.  Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. , 2012, Blood.

[40]  T. Habermann,et al.  The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma , 2012, Leukemia & lymphoma.

[41]  F. Angrilli,et al.  Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi , 2012, British journal of haematology.

[42]  T. Habermann,et al.  Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma , 2012, Haematologica.

[43]  P. Allavena,et al.  Immunology in the clinic review series; focus on cancer: tumour‐associated macrophages: undisputed stars of the inflammatory tumour microenvironment , 2012, Clinical and experimental immunology.

[44]  E. Morii,et al.  Tumour‐associated macrophages in diffuse large B‐cell lymphoma: a study of the Osaka Lymphoma Study Group , 2012, Histopathology.

[45]  J. Burger,et al.  The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. , 2011, Seminars in cancer biology.

[46]  A. Rosenwald,et al.  Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. , 2011, Blood.

[47]  T. Habermann,et al.  The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma , 2011, Leukemia.

[48]  I. Shih,et al.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis , 2011, Modern Pathology.

[49]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[50]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[51]  B. Sander,et al.  Impact of TP53 mutation and 17p deletion in mantle cell lymphoma , 2011, Leukemia.

[52]  A. Alavi,et al.  Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma. , 2011, Clinical lymphoma, myeloma & leukemia.

[53]  S. Coupland.  The challenge of the microenvironment in B‐cell lymphomas , 2011, Histopathology.

[54]  Sonali M. Smith,et al.  The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. , 2010, Blood cells, molecules & diseases.

[55]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Mohty,et al.  Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  W. Klapper,et al.  Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. , 2010, Blood.

[58]  Steven J. M. Jones,et al.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[59]  E. Kimby,et al.  The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). , 2010, Blood.

[60]  A. Rosenwald,et al.  Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. , 2010, Cancer research.

[61]  L. Staudt,et al.  SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype , 2009, Haematologica.

[62]  F. Jardin,et al.  Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value , 2009, British journal of haematology.

[63]  Yasodha Natkunam,et al.  Characterization of D-Cyclin Proteins in Hematolymphoid Neoplasms: Lack of Specificity of Cyclins D2 and D3 Expression in Lymphoma Subtypes , 2009, Modern Pathology.

[64]  M. Ghielmini,et al.  How I treat mantle cell lymphoma. , 2009, Blood.

[65]  J. Leonard,et al.  Outcome of deferred initial therapy in mantle-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  E. Kimby,et al.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.

[67]  B. Sander,et al.  The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival , 2008, British journal of haematology.

[68]  L. Reiniger,et al.  The cut‐off levels of CD23 expression in the differential diagnosis of MCL and CLL , 2008, Hematological oncology.

[69]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[70]  A. Rosenwald,et al.  Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis , 2008, British journal of haematology.

[71]  E. Campo,et al.  Advances in the understanding of mantle cell lymphoma , 2008, British journal of haematology.

[72]  W. Klapper,et al.  Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. , 2008, Blood.

[73]  L. Mortelmans,et al.  Positron emission tomography in mantle cell lymphoma , 2008, Leukemia & lymphoma.

[74]  L. Staudt,et al.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Martin Dreyling,et al.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.

[76]  P. Allavena,et al.  Role of tumor-associated macrophages in tumor progression and invasion , 2006, Cancer and Metastasis Reviews.

[77]  S. Artavanis-Tsakonas,et al.  Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[78]  Karey Shumansky,et al.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). , 2005, Blood.

[79]  D. Pinkel,et al.  Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. , 2005, Blood.

[80]  D. Catovsky,et al.  A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. , 2003, Blood.

[81]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[82]  H Clevers,et al.  Roles of Sox4 in central nervous system development. , 2000, Brain research. Molecular brain research.

[83]  Raphael Kopan,et al.  Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain , 1998, Nature.

[84]  A. López-Guillermo,et al.  Mantle cell lymphoma , 1998, Seminars in hematology.

[85]  J. Gribben,et al.  Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. , 1997, Blood.

[86]  W. Hiddemann,et al.  Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. , 1997, Cancer research.

[87]  A. Pileri,et al.  Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. , 1997, Blood.

[88]  Christel Brou,et al.  Signalling downstream of activated mammalian Notch , 1995, Nature.

[89]  M. Ladetto,et al.  Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[90]  D. Rossi,et al.  NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation , 2016, Leukemia.

[91]  R. Dalla‐Favera,et al.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. , 2013, Blood.

[92]  Ryan D. Morin,et al.  Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. , 2012, Blood.

[93]  E. Campo,et al.  Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.